Uterine Cancer

Oncology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD1775Phase 21 trial
Active Trials
NCT03668340Active Not Recruiting49Est. Jul 2027
Varian Medical Systems
1 program
HyperSight cone beam computed tomographyN/A1 trial
Active Trials
NCT06904365RecruitingEst. Apr 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AstraZenecaAZD1775
Varian Medical SystemsHyperSight cone beam computed tomography

Clinical Trials (2)

Total enrollment: 49 patients across 2 trials

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Start: Oct 2018Est. completion: Jul 202749 patients
Phase 2Active Not Recruiting
NCT06904365Varian Medical SystemsHyperSight cone beam computed tomography

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

Start: Apr 2025Est. completion: Apr 2026
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 49 patients
2 companies competing in this space